June

Almac Clinical Services Incorp. (ACSI) (PDF) (June 30, 2026)

Veranova, L.P. (PDF) (June 30, 2026)

Catalent Pharma Solutions, LLC (PDF) (June 30, 2026)

Veterans Pharmaceuticals, Inc. (PDF) (June 30, 2026)

United States Pharmacopeial Convention (PDF) (June 30, 2026)

Placement of Bromazolam in Schedule I; Correction (PDF) (June 24, 2026)

Temporary Placement of O-Desmethyltramadol in Schedule I (PDF) (June 24, 2026)

Amanda Ward, N.D.; Decision and Order (PDF) (June 24, 2026)

Irina Gross, D.P.M.; Decision and Order (PDF) (June 24, 2026)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (June 17, 2026)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (June 17, 2026)

Arizona Department of Corrections (PDF) (June 17, 2026)

Scottsdale Research Institute (PDF) (June 17, 2026)

Veranova, L.P. (PDF) (June 17, 2026)

Aphena Pharma Solutions MD, LLC (PDF) (June 17, 2026)

Wedgewood Pharmacy LLC (PDF) (June 17, 2026)

Cerilliant Corporation (PDF) (June 15, 2026)

VHG Labs DBA LGC Standards (PDF) (June 15, 2026)

Veranova, L.P. (PDF) (June 15, 2026)

Ashley Vermillion, N.P.; Decision and Order (PDF) (June 10, 2026)

Final Rule: Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (PDF) (June 9, 2026)

CalCog Inc. (PDF) (June 8, 2026)

May

60-Day Notice: Student Volunteer Service Agreement (PDF) (May 28, 2026)

Proposed Rule: Placement of Diphenidine in Schedule I (PDF) (May 26, 2026)

Proposed Rule: Removal of Exemption Status for Inactive Butalbital Products (PDF) (May 26, 2026)

Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I (PDF) (May 22, 2026)

Final Rule: Authority of Drug Enforcement Administration Supervisory Diversion Investigators, Field Intelligence Managers, and Intelligence Group Supervisors To Sign and Issue Administrative Subpoenas (PDF) (May 21, 2026)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (May 20, 2026)

Proposed Rule: Revision of Applications for Manufacturing and Procurement Quotas (PDF) (May 20, 2026)

Organix Chemistry Solutions LLC (PDF) (May 20, 2026)

Amneal Pharmaceuticals, LLC (PDF) (May 20, 2026)

Benuvia Operations, LLC (PDF) (May 18, 2026)

Final Rule: Placement of CUMYL-PEGACLONE in Schedule I (PDF) (May 13, 2026)

Final Rule: Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance (PDF) (May 4, 2026)

ANI Pharmaceuticals Inc. (PDF) (May 4, 2026)

Patheon API Inc. (PDF) (May 4, 2026)

ANI Pharmaceuticals Inc. (PDF) (May 4, 2026)

Patheon Pharmaceuticals Inc. (PDF) (May 4, 2026)

Final Rule: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I (PDF) (May 1, 2026)

April

Final Rule: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements (PDF) (April 28, 2026)

Proposed Rulemaking: Rescheduling of Marijuana (PDF) (April 28, 2026)

Proposed Rulemaking; Withdrawal: Rescheduling of Marijuana; Withdrawal (PDF) (April 28, 2026)

Final Rule: Placement of MDMB-4en-PINACA in Schedule I (PDF) (April 24, 2026)

AJNA Biosciences (PDF) (April 21, 2026)

VA Cooperative Studies Program (PDF) (April 21, 2026)

Leading Pharma LLC (PDF) (April 21, 2026)

60-Day Notice: Drug Use Statement (PDF) (April 17, 2026)

Usona Institute, Inc. (PDF) (April 17, 2026)

Quagen Pharmaceuticals LLC (PDF) (April 17, 2026)

LTS Therapy Systems, LLC (PDF) (April 17, 2026)

Royal Emerald Pharmaceuticals (PDF) (April 17, 2026)

30-Day Notice: Title—Registration for Controlled Substances Act Data-Use Request (PDF) (April 13, 2026)

Final Rule: Designation of P2P Methyl Glycidic Acid as a List I Chemical (PDF) (April 3, 2026)

Blue Rabbit Veterinary LLC (PDF) (April 3, 2026)

Lipomed/LGC Standards (PDF) (April 3, 2026)

Purisys, LLC (PDF) (April 3, 2026)

Research Triangle Institute (PDF) (April 3, 2026)

Indivior Manufacturing LLC (PDF) (April 1, 2026)

Research Triangle Institute (PDF) (April 1, 2026)

Pharmaron Manufacturing Services (US) LLC (PDF) (April 1, 2026)

Royal Emerald Pharmaceuticals (PDF) (April 1, 2026)

Fisher Clinical Services, Inc. (PDF) (April 1, 2026)

Sterling Wisconsin, LLC (PDF) (April 1, 2026)

Fisher Clinical Services, Inc. (PDF) (April 1, 2026)

March

Chemtos, LLC (PDF) (March 30, 2026)

Usona Institute (PDF) (March 30, 2026)

Pharmaron Manufacturing Services (US) LLC (PDF) (March 30, 2026)

SpecGx LLC (PDF) (March 26, 2026)

Final Rule: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I (PDF) (March 23, 2026)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (March 20, 2026)

Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments (PDF) (March 20, 2026)

Siegfried Grafton, Inc. (PDF) (March 19, 2026)

SpecGx LLC (PDF) (March 19, 2026)

Patheon API Services, Inc. (PDF) (March 19, 2026)

Siegfried Grafton, Inc. (PDF) (March 19, 2026)

United States Pharmacopeial Convention (PDF) (March 19, 2026)

Sterling Wisconsin, LLC (PDF) (March 19, 2026)

Pisgah Laboratories Inc. (PDF) (March 19, 2026)

Temporary Placement of Bromazolam in Schedule I (PDF) (March 16, 2026)

Purisys, LLC (PDF) (March 13, 2026)

Pisgah Laboratories Inc. (PDF) (March 13, 2026)

Stepan Company (PDF) (March 13, 2026)

Lonza Tampa, LLC (PDF) (March 13, 2026)

Patheon API Services Inc. (PDF) (March 13, 2026)

Final Rule: Designation of Propionyl Chloride as a List I Chemical (PDF) (March 10, 2026)

Sigma Aldrich Research Biochemicals Inc. (PDF) (March 10, 2026)

Stepan Company (PDF) (March 4, 2026)

Catalent Greenville, Inc. (PDF) (March 4, 2026)

Amneal Pharmaceuticals, LLC (PDF) (March 4, 2026)

Parexel International, LLC (PDF) (March 4, 2026)

Restek Corporation (PDF) (March 4, 2026)

Maridose LLC (PDF) (March 4, 2026)

Patheon API Inc. (PDF) (March 4, 2026)

Restek Corporation (PDF) (March 4, 2026)

Final Rule: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act (PDF) (March 2, 2026)

February

John Bender, M.D.; Decision and Order (PDF) (February 13, 2026)

Scottsdale Research Institute (PDF) (February 13, 2026)

Siemens Healthcare Diagnostics, Inc. (PDF) (February 13, 2026)

S&B Pharma LLC DBA Norac Pharma (PDF) (February 13, 2026)

Scottsdale Research Institute (PDF) (February 13, 2026)

Final Rule: Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017 (PDF) (February 5, 2026)

S & B Pharma LLC DBA Norac Pharma (PDF) (February 4, 2026)

Sterling Pharma USA LLC (PDF) (February 4, 2026)

Mylan Inc. (PDF) (February 2, 2026)

Promega Corporation (PDF) (February 2, 2026)

Sharp Clinical Services, LLC (PDF) (February 2, 2026)

Medi-Physics Inc. DBA GE Healthcare (PDF) (February 2, 2026)